|Sonus Pharmaceuticals To Hold Second Quarter Conference Call On July 11, 2001
Jul 5, 2001
BOTHELL, Washington, July 5, 2001-Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS) announced today that it will release financial results for the second quarter and hold its quarterly conference call on July 11, 2001. The conference call will be held at 1:30 P.M. PDT, 4:30 P.M. EDT. To access the conference call via live webc...
|Sonus Pharmaceuticals Completes $4.9 Million Equity Financing
Jun 18, 2001
BOTHELL, Washington, June 18, 2001-Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS) announced today that it has raised $4.9 million of gross proceeds through a private placement of 1.7 million shares of Sonus common stock. The shares were purchased by a select group of investors including Orion Biomedical Fund, OrbiMed Advisors ...
|Sonus Pharmaceuticals Reports First Quarter 2001 Financial Results
Apr 11, 2001
BOTHELL, Washington, April 11, 2001-Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS) announced today financial results for the first quarter ended March 31, 2001. The Company also reported progress of its Phase 1 study with S-8184, an injectable paclitaxel emulsion product for cancer therapy. First Quarter 2001 Fin...
|Sonus Pharmaceuticals Signs Patent Licensing Agreement In Japan, South Korea And Taiwan
Jan 16, 2001
BOTHELL, Washington, January 16, 2001-Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS) announced today the signing of a patent licensing agreement with Chugai Pharmaceutical Co., Ltd. (Chugai) and Molecular Biosystems, Inc. (MBI). The agreement gives Chugai and MBI non-exclusive rights under certain Sonus patents to manufacture and s...
|Sonus Pharmaceuticals Enrolling Patients In Phase 1 Study With Novel Paclitaxel Formulation For Cancer Treatment
Jan 8, 2001
BOTHELL, Washington, January 8, 2001-Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS) announced today that patients are being enrolled in a Phase 1 clinical study with the Company's first drug delivery product, S-8184, an injectable paclitaxel emulsion formulation. Paclitaxel is the active ingredient in the highly successful drug...
- Corporate Governance
- Management & Board
- Stock Information
- SEC Filings
- Quarterly Results
- Analyst Coverage
- Webcasts & Presentations
- Scientific Publications & Presentations
- Frequently Asked Questions
© 2004-2017 OncoGenex Pharmaceuticals Inc. All rights reserved.
OncoGenex product candidates are investigational drugs for use only in approved clinical trials.
OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.
OncoGenex is uniquely focused on the challenge of cancer treatment resistance. We currently have several on-going clinical trials that may be of interest to you.
OncoGenex focuses on diverse molecular entities that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.
OncoGenex develops novel compounds designed to meet the persistent challenge of treatment resistance across a variety of cancers.